Current Hematologic Malignancy Reports

, Volume 7, Issue 2, pp 109–115

Clinical Trials in Chronic Myeloid Leukemia

Chronic Myeloid Leukemia (J Goldman, Section Editor)


The introduction of the tyrosine kinase inhibitor (TKI) imatinib in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) has substantially improved the outcome of CML patients. Despite the positive results, problems and questions remained. This was the rationale to setup trials for treatment optimization, where imatinib was administered in higher dose and/or in combination with other therapy but where also new and potentially more efficacious second-generation TKI, nilotinib and dasatinib, were investigated. This review summarizes data of recently published first-line studies with the standard treatment imatinib 400 mg as one study arm. Results of randomized comparisons to higher-dose imatinib treatment, nilotinib or dasatinib are discussed. With regard to outcome interpretation, general aspects on statistical issues and endpoint definitions are put into focus. Considering decidedly increased longevity thanks to TKI treatment, future research should include the evaluation of the quality of life (QoL). Relating also to QoL, safe ways of drug discontinuation need to be investigated.


Chronic myeloid leukemia Clinical trials TKI Imatinib Dasatinib Nilotinib Molecular remission (response) Cytogenetic remission (response) Competing risk Cumulative incidence Composite endpoints Progression-free survival Overall survival Stopping Cure 

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Universitätsmedizin Mannheim, Universität HeidelbergMannheimGermany
  2. 2.Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (IBE)Ludwig-Maximilians-Universität MünchenMünchenGermany

Personalised recommendations